Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7646

Shown on this page

Current sort

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Interventions: Vamifeport, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Acute Ischemic Stroke
Interventions: RapidPulseTM Aspiration System; Device
Lead sponsor: RapidPulse, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Torrance, California • New Haven, Connecticut • Jacksonville, Florida + 15 more

Conditions: Oligometastatic Prostate Cancer (OMPC)
Interventions: AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: Aneurysm, Aneurysm, Intracranial
Interventions: Surpass Elite with Guardian Flow Diverter System; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Tucson, Arizona • Davis, California • Los Angeles, California + 17 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 217
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 76 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 259
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more

Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Interventions: TNG456, abemaciclib; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more

Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more

Conditions: Leukemia
Interventions: cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 59 Years
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more

Clinical trials in Jacksonville, Florida

Filter and sort this location

Institutions in Jacksonville

Live official records

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Vancomycin for Primary Sclerosing Cholangitis

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia